Patients will be assigned to one group or the other based upon the location in your body of your cancer, whether your cancer is new or has returned, and whether you live in the United States or Europe. Other than these factors, the assignment will be determined only by chance (randomization) and neither you, the study doctor, nor SurgiMab, the study sponsor, will decide to which group you will be assigned. Patients will be assigned to one group or the other following the completion of all screening assessments and after confirmation of their eligibility So you will not know whether or not you will receive SGM-101 when you agree to participate in the study, but you will be told prior to your surgery if you will receive it.
How understandable was the trial content above?
Hard to understand
Easy to understand
